Profile data is unavailable for this security.
About the company
Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.
- Revenue in USD (TTM)431.38k
- Net income in USD-2.82m
- Incorporated--
- Employees3.00
- LocationAptorum Group Ltd17 Hanover SquareLONDON W1S 1BNUnited KingdomGBR
- Phone+44 208 092 9299
- Fax+44 203 928 8277
- Websitehttp://www.aptorumgroup.com/
More ▼
Mergers & acquisitions
| Acquired company | APM:NAQ since announced | Transaction value |
|---|---|---|
| YOOV Group Holding Ltd | -17.24% | -- |
Data delayed at least 15 minutes, as of Nov 12 2024 20:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alzamend Neuro Inc | 0.00 | -7.39m | 6.71m | 4.00 | -- | -- | -- | -- | -10.69 | -10.69 | 0.00 | -1.41 | 0.00 | -- | -- | 0.00 | -344.10 | -177.86 | -- | -257.81 | -- | -- | -- | -- | -- | -363.62 | -- | -- | -- | -- | 33.14 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -17.91m | 6.90m | 10.00 | -- | 2.20 | -- | -- | -75.48 | -75.48 | 0.00 | 0.182 | 0.00 | -- | -- | 0.00 | -334.48 | -133.14 | -973.00 | -181.26 | -- | -- | -- | -- | -- | -90.11 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Ainos Inc | 65.12k | -15.41m | 6.92m | 46.00 | -- | 0.1783 | -- | 106.24 | -3.17 | -3.17 | 0.0126 | 2.80 | 0.0019 | 0.7814 | 13.86 | 1,415.65 | -44.29 | -36.36 | -49.13 | -58.33 | -316.62 | 36.82 | -23,664.28 | -813.63 | 1.45 | -55.50 | 0.4016 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Cyclerion Therapeutics Inc | 0.00 | -10.47m | 6.96m | 1.00 | -- | 0.7362 | -- | -- | -4.26 | 1.27 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -103.82 | -72.70 | -150.23 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.51m | -13.23m | 7.02m | 20.00 | -- | -- | -- | 1.27 | -3.05 | -3.05 | 1.19 | -1.34 | 0.4336 | -- | -- | 275,450.00 | -104.14 | -59.18 | -- | -133.04 | -- | -- | -240.15 | -470.45 | -- | -4.17 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Moleculin Biotech Inc | 0.00 | -25.17m | 7.14m | 18.00 | -- | 0.363 | -- | -- | -11.62 | -11.62 | 0.00 | 6.91 | 0.00 | -- | -- | 0.00 | -69.24 | -46.84 | -83.35 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Viracta Therapeutics Inc | 0.00 | -45.34m | 7.14m | 40.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | 0.0678 | 0.00 | -- | -- | 0.00 | -83.82 | -86.35 | -140.98 | -106.38 | -- | -- | -- | -11,853.94 | -- | -59.78 | 0.8753 | -- | -- | -- | -3.78 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 7.24m | 3.00 | -- | 0.269 | -- | 16.77 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Mosaic Immunoengineering Inc | 0.00 | -1.21m | 7.24m | 3.00 | -- | -- | -- | -- | -0.1674 | -0.1674 | 0.00 | -0.8904 | 0.00 | -- | -- | 0.00 | -634.64 | -- | -- | -- | -- | -- | -- | -- | -- | -14.05 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 354.91k | -545.87k | 7.39m | 2.00 | -- | -- | -- | 20.82 | -0.00005 | -0.00005 | 0.00003 | -0.0001 | 8.98 | -- | 15.71 | 177,455.00 | -1,381.60 | -- | -- | -- | 87.28 | -- | -153.81 | -- | -- | -2.16 | -- | -- | -21.46 | -- | 36.92 | -- | -- | -- |
| Pulmatrix Inc | 11.39m | -10.84m | 7.56m | 22.00 | -- | 0.5677 | -- | 0.6633 | -2.97 | -2.97 | 3.12 | 3.64 | 0.483 | -- | 21.64 | 517,818.20 | -45.97 | -46.91 | -52.76 | -58.12 | -- | -- | -95.18 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Edesa Biotech Inc | 0.00 | -6.93m | 7.57m | 16.00 | -- | 2.64 | -- | -- | -2.21 | -2.21 | 0.00 | 0.8829 | 0.00 | -- | -- | 0.00 | -94.60 | -- | -128.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| GlucoTrack Inc | 0.00 | -12.05m | 7.72m | 6.00 | -- | -- | -- | -- | -2.42 | -2.42 | 0.00 | -0.6004 | 0.00 | -- | -- | 0.00 | -251.32 | -94.01 | -493.89 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | -- | -- | -- | -- | -60.02 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.06m | 7.74m | 1.00 | -- | -- | -- | -- | -0.0017 | -0.0017 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -32.46 | -- | -46.53 | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | -- | -- | -14.64 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -17.23m | 7.75m | 7.00 | -- | -- | -- | -- | -13.51 | -13.51 | 0.00 | -0.9847 | 0.00 | -- | -- | 0.00 | -185.82 | -87.52 | -362.29 | -116.56 | -- | -- | -- | -- | -- | -1,596.37 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Aptorum Group Ltd's reporting currency: US Dollar USD
2.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 30 Jun 2024 | 39.85k | 1.36% |
| Citadel Securities LLCas of 30 Jun 2024 | 17.02k | 0.58% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 11.51k | 0.39% |
| UBS Securities LLCas of 30 Jun 2024 | 7.42k | 0.25% |
| NewEdge Advisors LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Tower Research Capital LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Murchinson Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
